Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumars�ureestern

Gutzmer, Ralf; Kapp, Alexander; Werfel, Thomas

doi:10.1007/s00105-004-0728-1

Cited by 16 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with FAEs has been reported to be effective in small case series and case reports of patients with sarcoidosis [5,6,11,12,13,14], while marked to complete remission of skin and pulmonary lesions has been reported (table 1). Dümmler et al [11] presented 2 patients with cutaneous sarcoidosis treated with FAEs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-Organ Sarcoidosis Treatment with Fumaric Acid Esters: A Case Report and Review of the Literature

Zouboulis

Lippert²,

Karagiannidis³

2014

Dermatology

View full text Add to dashboard Cite

Sarcoidosis is a rare, systemic disease that is characterized by the formation of granulomas in various organs, including the skin. As the etiology remains unknown, the treatment of sarcoidosis is challenging. We present a 47-year-old female patient with progressive, multi-organ sarcoidosis who had a complete clinical improvement of the skin lesions, a moderate reduction in pulmonary opacities on chest X-ray, a marked subjective improvement in general status and pulmonary efficiency and a marked reduction in serum angiotensin-converting enzyme and soluble interleukin-2 receptor after 6 months of therapy with fumaric acid esters. The present case and similar reports in the literature highlight the probable efficacy of fumaric acid esters in the treatment of sarcoidosis and other non-infectious, granulomatous diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The side effects included flush, minor gastrointestinal complaints and lymphopenia. Gutzmer et al [13] demonstrated a 61-year-old female patient with cutaneous sarcoidosis treated with FAEs. After 12 months of therapy, lesions were markedly improved and treatment was discontinued.…”

Section: Discussionmentioning

confidence: 99%

Multi-Organ Sarcoidosis Treatment with Fumaric Acid Esters: A Case Report and Review of the Literature

Zouboulis

Lippert²,

Karagiannidis³

2014

Dermatology

View full text Add to dashboard Cite

show abstract

“…The mechanisms of action of fumaric acid esters would appear to offer a potential for treatment in this immunological setting. The literature contains reports of sarcoidosis patients with cutaneous as well as systematic disease who have been treated with fumaric acid esters (Table 2) [35, 45]. Treatment was successful not only in cutaneous disease but also with a large portion of patients with systemic disease.…”

Section: Sarcoidosismentioning

confidence: 99%

Dimethyl fumarate – only an anti‐psoriatic medication?

Meißner

Valesky

Kippenberger

et al. 2012

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Fumaric acid esters have been used successfully in the therapy of psoriasis vulgaris since 1959. In the last 17 years, many of the underlying mechanisms of anti‐psoriatic action, such as a Th1/Th2 shift, a suppression of important leukocyte adhesion molecules, the induction of pro‐apoptotic pathways in T‐cells and recently anti‐angiogenic action, have been discovered. Based on the knowledge of these immunomodulatory characteristics, fumaric acid esters have been shown to be effective or potentially effective in a multitude of dermatological as well as non‐dermatological diseases. The range of new therapeutic targets reaches from multiple sclerosis to illnesses such as necrobiosis lipoidica, granuloma annulare and sarcoidosis. Experimental approaches offer promising, although preliminary, results on the treatment of cancer, malaria, chronic inflammatory lung diseases, and Huntington disease, to name but a few. This valued and well‐known drug mainly prescribed by dermatologists is now experiencing a renaissance far beyond dermatologic applications.

show abstract

“…Den Erkenntnissen über die zentrale Rolle der Th1-typischen Zytokine Rechnung tragend, wurde bereits auch über erfolgreiche Behandlungen mit topischen Immunmodulatoren wie Tacrolimus und systemischen Therapien mit Ciclosporin A und sogar TNF-α-Inhibitoren wie Adalimumab oder Infliximab berichtet. Diese "off-label" eingesetzten Mittel sollten dann in Erwägung gezogen werden, wenn andere Therapien versagen [3,4,5,6].…”

Section: Diskussionunclassified

Seltene ulzerierende kutane und systemische Sarkoidose

et al. 2011

View full text Add to dashboard Cite

Sarcoidosis is a granulomatous multisystemic disease of unclear etiology, which can affect any organ. The cutaneous manifestations are variable, but ulcerative cutaneous sarcoidosis is very rare. One must rule out other granulomatous skin diseases, especially necrobiosis lipoidica. There is no standarized therapy; usually an interdisciplinary approach over years taking multiple side effects into consideration is needed. A 58-year-old woman with a long history of cutaneous, nodal and pulmonary sarcoidosis suddenly developed ulcerations within the disseminated skin lesions on her legs. The combination of systemic hydroxychloroquine and modern wound management lead to complete healing of the ulcers and a significant improvement in the remaining skin lesions.

show abstract

Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumars�ureestern

Cited by 16 publications

References 24 publications

Multi-Organ Sarcoidosis Treatment with Fumaric Acid Esters: A Case Report and Review of the Literature

Multi-Organ Sarcoidosis Treatment with Fumaric Acid Esters: A Case Report and Review of the Literature

Dimethyl fumarate – only an anti‐psoriatic medication?

Seltene ulzerierende kutane und systemische Sarkoidose

Contact Info

Product

Resources

About